We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+7.61%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$502M
AUM Growth
-$22.7M
Cap. Flow
-$16.4M
Cap. Flow %
-3.26%
Top 10 Hldgs %
48.75%
Holding
84
New
17
Increased
18
Reduced
14
Closed
28

Top Buys

Rank Stock Value
1
JBIO
Jade Biosciences
JBIO
+$38.4M
2
ISRG icon
Intuitive Surgical
ISRG
+$14.2M
3
RGEN icon
Repligen
RGEN
+$13.6M
4
GMAB icon
Genmab
GMAB
+$13.3M
5
HNGE
Hinge Health
HNGE
+$13M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.1M
2
HUM icon
Humana
HUM
+$13.3M
3
GKOS icon
Glaukos
GKOS
+$13.2M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$9.93M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$9.48M

Sector Composition

Rank Sector Weight
1 Healthcare 99.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNDX icon
51
Syndax Pharmaceuticals
SNDX
$1.85B
$1.4M 0.28%
150,000
-775,000
-84% -$8.53M
SCYX icon
52
SCYNEXIS
SCYX
$36.1M
$829K 0.17%
153,614
– –
KPTI icon
53
Karyopharm Therapeutics
KPTI
$163M
$580K 0.12%
134,566
– –
ALT icon
54
Altimmune
ALT
$570M
$406K 0.08%
+105,000
New +$568K
ELVN icon
55
Enliven Therapeutics
ELVN
$3.84B
$227K 0.05%
11,300
– –
RVPH
56
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
$52.6K 0.01%
6,900
– –
ACAD icon
57
Acadia Pharmaceuticals
ACAD
$4.39B
– –
-169,000
Closed -$2.81M
AGL icon
58
Agilon Health
AGL
$1.57B
– –
-12,204
Closed -$1.32M
ARVN icon
59
CALL
Arvinas
ARVN
$536M
– –
-750,000
Closed -$5.26M
AVTR icon
60
Avantor
AVTR
$8.09B
– –
-453,000
Closed -$7.34M
BHVN icon
61
Biohaven
BHVN
$2.21B
– –
-145,000
Closed -$3.49M
BPMC
62
DELISTED
Blueprint Medicines
BPMC
– –
-68,500
Closed -$6.06M
BRKR icon
63
Bruker
BRKR
$9.14B
– –
-115,000
Closed -$4.8M
CAPR icon
64
Capricor Therapeutics
CAPR
$389M
– –
-239,000
Closed -$2.27M
CNTA
65
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-529,000
Closed -$7.61M
GKOS icon
66
Glaukos
GKOS
$8.81B
– –
-134,000
Closed -$13.2M
GMAB icon
67
CALL
Genmab
GMAB
$17.8B
– –
-433,100
Closed -$8.48M
HUM icon
68
CALL
Humana
HUM
$46.2B
– –
-80,000
Closed -$21.2M
HYPR icon
69
Hyperfine
HYPR
$94.9M
– –
-222,174
Closed -$159K
IDYA icon
70
IDEAYA Biosciences
IDYA
$3.5B
– –
-445,000
Closed -$7.29M
IONS icon
71
Ionis Pharmaceuticals
IONS
$9.27B
– –
-60,000
Closed -$1.81M
JANX icon
72
Janux Therapeutics
JANX
$972M
– –
-258,000
Closed -$6.97M
JAZZ icon
73
Jazz Pharmaceuticals
JAZZ
$16B
– –
-80,000
Closed -$9.93M
LXEO icon
74
Lexeo Therapeutics
LXEO
$360M
– –
-645,000
Closed -$2.24M
MIRM icon
75
Mirum Pharmaceuticals
MIRM
$6.95B
– –
-40,000
Closed -$1.8M
1 2
3
4

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q2 2025 Portfolio in Review

As of Q2 2025, Avidity Partners Management held 84 positions worth $502M, down 4.3% from $525M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Avidity Partners Management withdrew a net $16.4M in Q2 2025, closing 28 positions and reducing 14 holdings. Its most notable exit was Regeneron Pharmaceuticals, an estimated $16.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 91% a quarter earlier.

Against the trend, Avidity Partners Management opened a new position in Jade Biosciences worth $11.3M.

  • Avidity Partners Management's largest Q2 2025 buy was Jade Biosciences: 1,127,186 shares worth $11.3M.
  • Avidity Partners Management added most to CG Oncology in Q2 2025, an estimated $12.5M increase.
  • Avidity Partners Management's biggest Q2 2025 reduction was Humana, cutting an estimated $13.3M.
  • Avidity Partners Management fully exited Regeneron Pharmaceuticals in Q2 2025, selling an estimated $16.1M.
  • Avidity Partners Management's ten largest holdings make up 49% of its $502M portfolio in Q2 2025.
  • Avidity Partners Management opened 17 new positions and closed 28 in Q2 2025.
  • Avidity Partners Management's portfolio value fell 4.3% quarter-over-quarter to $502M.

Based on Avidity Partners Management's 13F filing for Q2 2025, filed 14 Aug 2025.